Revenio Group Oyj - Financial Statement Release

Revenio Group Corporation: Interim Report January 1 - March 31, 2015: Strong first quarter - considerable growth in net sales and operating profit

Revenio Group Corporation Stock Exchange Release April 24, 2015 at 9:00

Revenio Group Corporation Interim Report, January 1-March
31, 2015

Revenio Group Corporation is adopting the publication procedure enabled by the
Financial Supervisory Authority's Regulations and guidelines 7/2013 (Disclosure
obligation on issuers) and is publishing its Interim Report for January-March
2015 as an appendix to this stock exchange release. This stock exchange release
is a summary of the Revenio Group Corporation's Interim Report for January-March
2015. The Interim Report can be read in full in the PDF appendix to this
release. The Interim Report is also available on Revenio's website:
http://www.revenio.fi.

STRONG FIRST QUARTER FOR REVENIO
- CONSIDERABLE GROWTH IN NET SALES AND OPERATING PROFIT

January-March in brief, continuing Group functions:

  * Net sales EUR 4.6 (3.7) million, growth 24.4%
  * Operating profit EUR 1.4 (1.1) million, growth 26.8%
  * Undiluted earnings per share 0.16 (0.12), diluted earnings per share 0.15
    (0.12)
  * Cash and cash equivalents EUR 5.1 (4.0) million
  * Equity ratio 69.7 (63.7)%
  * During the review period, in February, the Group announced the licensing of
    technologies related to the detection of asthma and skin cancer and the
    intention to commercialize these technologies. The projects have proceeded
    according to plan
  * The sale of Boomeranger Boats Oy in February supports the Group's focus on
    health technology
  * Revenio's NASDAQ OMX ICB classification changed to Health Care on March
    3, 2015
  * From the beginning of May, CEO Olli-Pekka Salovaara will temporarily
    relocate to the United States, which reflects the central role of this
    market in the health technology industry
  * The growth of probe sales continued strong, amounting to 2.3 (1.8) million
    pcs, up by 27% from the previous year
  * During the review period, we made headway in the clinical trials related to
    the Icare HOME tonometer's FDA license in the United States

Key figures, Continuing operations, MEUR:

 Key Figures, MEUR:

                                      1-3/2015      1-3/2014           Change-%

 Net sales, Group                          4.6           3.7               24.4

 Operating profit, Group                   1.4           1.1               26.8

 Net sales, Health Tech                    4.6           3.7               24.4

 Operating profit, Health Tech             1.7           1.4               23.3

 Undiluted earnings per share             0.16          0.12               14.3

 Diluted earnings per share               0.15          0.12               15.5

 Cash flow from operating
 activities                                3.1           0.1             3000.0

                                 31 March 2015 31 March 2014 Change, %-   point

 Equity ratio-%                           69.7          63,7                6.0

 Gearing-%                               -38.5         -14,7               23.8


Financial guidance

The net sales and operating profit of Icare are expected to grow from last year.
Investments in new business operations related to health tech, which have an
impact on consolidated operating profit and cash flow. No significant
investments will be made in 2015.

Outlook

In the next few years, health care will face considerable challenges everywhere
in the world. Aging populations, the proliferation of chronic diseases,
increasing inequality and, most of all, the increasing costs of health care,
will force national economies to look for more efficient ways to treat and
prevent diseases having a major impact on public health. Screening and the
related technologies play a key role in this development. The screening market
is global, and too little screening is still performed in relation to the
potential benefits. In contrast to the development of new pharmaceuticals,
screening does not require prolonged clinical trials; rather, the benefits can
be achieved with quick and precise referral for treatment.

Revenio's role in the screening process is to produce simple and easy-to-use
methods, devices and technologies to replace old-fashioned and inefficient
operating models.

Olli-Pekka Salovaara, President and CEO, comments on the first quarter results:"As expected, the first quarter of 2015 got off to a strong start. Our net sales
grew by 24.4% and we enjoyed excellent profitability, despite investments in new
growth areas. The considerable strengthening of the US dollar has a positive
impact on our result as we exchanged USD deposits for euros in 2014 and during
the first quarter of 2015.

From March 2015, Revenio is a health tech group according to the NASDAQ OMX ICB
classification, with Health Care as its official industry classification. Our
goal is global market leadership in eye pressure measurement products. In the
evolution of technologies related to the measurement of eye pressure, Icare is
in the process of displacing competing products based on traditional methods,
which has enabled us to win market shares in our key markets. Our new health
tech R&D projects announced during the review period tackle global public health
challenges in which the common denominator is a pressing need to make cost
savings in health care via preventive measures. We will revolutionize these
markets by introducing leading screening technologies used by health care
professionals everywhere in the world. We are systematically launching new,
easy-to-use and cost-effective products for screening and monitoring for
diseases with a major impact on public health.

In February, we sold the entire share capital of Technology and Services segment
subsidiary Boomeranger Boats Oy, which had been transferred to discontinued
operations.  We are focusing on health technology in accordance with our
strategy, and the sale of a company not operating in this core field of business
supports the realization of the strategy.

Icare's tonometers sold well in all key markets during the review period. The
sales of Icare HOME tonometer have picked up speed. According to feedback from
experts, there is clear demand for this product that will change current
treatment practice. In the United States, the clinical trials related to our FDA
license application have progressed well during the review period, but it is
still too early to say when we will be in a position to file the application.
Probe sales have maintained a strong growth, which provides a stable and
constantly expanding foundation for Icare's device sales.

For its part, the Oscare Sono(TM) osteoporosis detection device has attracted a
great deal of interest in the market during the review period. The device is an
excellent screening method for DXA, which represents the current standard. We
will therefore once again help society to save on costs, as patients needing
more detailed examinations can be referred to further tests on the basis of
screening.

The operations of Revenio Research Oy, the subsidiary that we established in
December, have been initiated according to plan.  Our projects related to asthma
and skin cancer detection technologies progressed according to plan in Q1. It
should be noted, however, that even though both products have been tested by
experts and received excellent assessments, we do not expect a commercial impact
from these products for a few years yet.

From the beginning of May, I will be working from the United States, which
reflects the crucial role of the US market as the largest market area for health
technology. Through our presence in this market area, we will be able to better
support our local distribution network and our own organization, and make them
even better. Local presence is important also in terms of moving the FDA process
forward. The most important reason for my moving to the US is to build personal
relationships with the customer base, our distributors and physicians in
decision-making positions."

General clause

This release contains certain forward-looking statements that are based on
management's current assumptions. Due to their nature, these statements involve
risks and uncertainty, and are sensitive to changes in the economy or industry.

Revenio Group Corporation
Board of Directors

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
margin for continuing operations standing at 27.5%. Revenio Group Corporation
has been listed in NASDAQ OMX Helsinki.


[HUG#1913853]

Attachments:

Revenio Group Corporation Interim Report Q1 2015.pdf